The authors discuss the limitations of CAR-T and strategies to overcome them, specifically in the context of B cell acute lymphoblastic leukemia, including the use of allogeneic CAR-T, dual-targeted CAR-T, and combination strategies with novel technologies and agents.
[Biomarker Research]

Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News